Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment

Cell Death and Disease

Volumn 5, Issue 7, 2014, Pages

  Ciavardelli, D ^a,b   Rossi, C ^b   Barcaroli, D ^b   Volpe, S ^c   Consalvo, A ^b   Zucchelli, M ^b   De Cola, A ^c   Scavo, E ^c   Carollo, R ^b   D'Agostino, D ^b   Forli F ^b   D'Aguanno, S ^d   Todaro, M ^c   Stassi, G ^c   Di Ilio, C ^b   De Laurenzi, V ^b   Urbani, A ^d,e  

^a KORE UNIVERSITY OF ENNA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; DOXORUBICIN; GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LACTATE DEHYDROGENASE; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ADHERENT CELL; ARTICLE; BREAST CANCER; CANCER STEM CELL; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENRICHMENT CULTURE; ENZYME ACTIVITY; FERMENTATION; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; METABOLOMICS; MITOCHONDRIAL RESPIRATION; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; BREAST TUMOR; ENZYMOLOGY; FEMALE; METABOLISM; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DEOXYGLUCOSE; FEMALE; GLYCOLYSIS; HUMANS; L-LACTATE DEHYDROGENASE; NEOPLASTIC STEM CELLS; OXIDATIVE PHOSPHORYLATION; PYRUVATE KINASE;

EID: 84905513845     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.285     Document Type: Article

References (66)

1. Al-Hajj M,Wicha MS, Benito-Hernandez A,Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988
2. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010; 28: 4006-4012
3. Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2013; e-pub ahead of print 7 October 2013; doi:10.1038/onc.2013.411
4. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4: e532
5. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013; 12: 829-846
6. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033
7. Menendez JA, Joven J, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Cuyas E et al. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle 2013; 12: 1166-1179
8. Pecqueur C, Oliver L, Oizel K, Lalier L, Vallette FM. Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol 2013; 2013: 805975
9. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 2013; 23: 316-331
10. Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L et al. Effective elimination of cancer stem cells by a novel drug combination strategy. Stem Cells 2013; 31: 23-34
11. Palorini R, Votta G, Balestrieri C, Monestiroli A, Olivieri S, Vento R et al. Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS. J Cell Biochem 2014; 115: 368-379
12. Gammon L, Biddle A, Heywood HK, Johannessen AC, Mackenzie IC. Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism. PLoS One 2013; 8: e62493
13. Zhou Y, Zhou Y, Shingu T, Feng L, Chen Z, Ogasawara M et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem 2011; 286: 32843-32853
14. Morfouace M, Lalier L, Bahut M, Bonnamain V, Naveilhan P, Guette C et al. Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J Biol Chem 2012; 287: 33664-33674
15. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 2011; 108: 16062-16067
16. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9: 425-434
17. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233
18. Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L et al. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 2011; 140: 297-309
19. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 2014; e-pub ahead of print 17 February 2014; doi:10.1038/onc.2014.5
20. Todaro M, Turdo A, Bartucci M, Iovino F, Dattilo R, Biffoni M et al. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res 2013; 73: 6393-6400
21. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-472
22. Milane L, Duan Z, Amiji M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int 2011; 11: 3
23. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47
24. Koukourakis MI, Pitiakoudis M, Giatromanolaki A, Tsarouha A, Polychronidis A, Sivridis E et al. Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Sci 2006; 97: 1056-1060
25. Lu H, Shah P, Ennis D, Shinder G, Sap J, Le-Tien H et al. The differentiation of skeletal muscle cells involves a protein-tyrosine phosphatase-alpha-mediated C-Src signaling pathway. J Biol Chem 2002; 277: 46687-46695
26. Anderson KM, Tsui P, Guinan P, Rubenstein M. The proliferative response of hela cells to 2-deoxy-D-glucose under hypoxic or anoxic conditions: an analogue for studying some properties of in vivo solid cancers. Anticancer Res 2006; 26: 4155-4162
27. Brown JM. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59: 5863-5870
28. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr 2007; 39: 251-257
29. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010; 329: 1492-1499
30. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-308
31. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005; 44: 9417-9429
32. Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012; 491: 458-462
33. Bluemlein K, Gluckmann M, Gruning NM, Feichtinger R, Kruger A, Wamelink M et al. Pyruvate kinase is a dosage-dependent regulator of cellular amino acid homeostasis. Oncotarget 2012; 3: 1356-1369
34. Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA 2012; 109: 6904-6909
35. Bauer DE, Harris MH, Plas DR, Lum JJ, Hammerman PS, Rathmell JC et al. Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J 2004; 18: 1303-1305
36. Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, Gay LJ et al. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J Clin Invest 2013; 123: 1068-1081
37. Gogvadze V, Norberg E, Orrenius S, Zhivotovsky B. Involvement of Ca2+ and ROS in alpha-tocopheryl succinate-induced mitochondrial permeabilization. Int J Cancer 2010; 127: 1823-1832
38. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011; 334: 1278-1283
39. Nakano A, Tsuji D, Miki H, Cui Q, El Sayed SM, Ikegame A et al. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One 2011; 6: e27222
40. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004; 64: 31-34
41. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P et al. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 2006; 26: 3561-3566
42. Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 2011; 71: 4585-4597
43. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001; 294: 1102-1105
44. Yamaguchi R, Perkins G. Finding a panacea among combination cancer therapies. Cancer Res 2012; 72: 18-23
45. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010; 102: 1637-1652
46. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000; 275: 33585-33592
47. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 2004; 279: 25535-25543
48. Coleman MC, Asbury CR, Daniels D, Du J, Aykin-Burns N, Smith BJ et al. 2-deoxy-Dglucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 2008; 44: 322-331
49. Shutt DC, O'Dorisio MS, Aykin-Burns N, Spitz DR. 2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells. Cancer Biol Ther 2010; 9: 853-861
50. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402
51. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279
52. Ciavardelli D, D'Orazio M, Pieroni L, Consalvo A, Rossi C, Sacchetta P et al. Proteomic and ionomic profiling reveals significant alterations of protein expression and calcium homeostasis in cystic fibrosis cells. Mol Biosyst 2013; 9: 1117-1126
53. Ciavardelli D, Ammendola S, Ronci M, Consalvo A, Marzano V, Lipoma M et al. Phenotypic profile linked to inhibition of the major Zn influx system in Salmonella enterica: proteomics and ionomics investigations. Mol Biosyst 2011; 7: 608-619
54. D'Aguanno S, D'Agnano I, De Canio M, Rossi C, Bernardini S, Federici G et al. Shotgun proteomics and network analysis of neuroblastoma cell lines treated with curcumin. Mol Biosyst 2012; 8: 1068-1077.
55. D'Aguanno S, D'Alessandro A, Pieroni L, Roveri A, Zaccarin M, Marzano V et al. New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation. J Proteome Res 2011; 10: 416-428
56. Vissers JP, Langridge JI, Aerts JM. Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. Mol Cell Proteomics 2007; 6: 755-766
57. Kanani H, Chrysanthopoulos PK, Klapa MI. Standardizing GC-MS metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 871: 191-201
58. Sirolli V, Rossi C, Di Castelnuovo A, Felaco P, Amoroso L, Zucchelli M et al. Toward personalized hemodialysis by low molecular weight amino-containing compounds: future perspective of patient metabolic fingerprint. Blood Transfus 2012; 10(Suppl 2): s78-s88
59. Rizza S, Copetti M, Rossi C, Cianfarani MA, Zucchelli M, Luzi A et al. Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. Atherosclerosis 2014; 232: 260-264
60. Shimada N, Shinagawa T, Ishii S. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells 2008; 13: 245-254
61. Krieg AF, Rosenblum LJ, Henry JB. Lactate dehydrogenase isoenzymes a comparison of pyruvate-to-lactate and lactate-to-pyruvate assays. Clin Chem 1967; 13: 196-203
62. Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P et al. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis 2013; 4: e612
63. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem 1976; 72: 248-254
64. Lohr GW, Waller HD. Glucose-6-phosphate dehydrogenase. Bergmeyer HU (ed). Methods of Ezymatic Analysis. Academic Press: New York, 1974, p 636
65. Matsumura H, Miyachi S. Cycling assay for nicotinamide adenine dinucleotides. Methods Enzymol 1980; 69: 465-470
66. Wobbrock JO, Findlater L, Gergle D, Higgins JJ. The aligned rank transform fornonparametric factorial analyses using only ANOVA procedures. Proceedings of the ACM Conference on Human Factors in computing systems (CH'11); 7-12 May, 2011. Vancouver, British Columbia, Canada. ACM Press: New York, NY, USA, 2011, pp 143-146